

Taku Okazaki

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9474590/taku-okazaki-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69
papers

18,302
citations

42
h-index

70
g-index

70
ext. papers

20,915
ext. citations

11.1
avg, IF

6.19
L-index

#	Paper	IF	Citations
69	PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity.. <i>Nature Immunology</i> , 2022 ,	19.1	4
68	Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity.. <i>Immunity</i> , 2022 ,	32.3	5
67	T-cell-intrinsic and -extrinsic regulation of PD-1 function. <i>International Immunology</i> , 2021 , 33, 693-698	4.9	0
66	PD-1 preferentially inhibits the activation of low-affinity T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	1
65	PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation. <i>Molecular Cell</i> , 2020 , 77, 937-950.e6	17.6	15
64	LAG-3: from molecular functions to clinical applications 2020 , 8,		70
63	Restriction of PD-1 function by -PD-L1/CD80 interactions is required for optimal T cell responses. <i>Science</i> , 2019 , 364, 558-566	33.3	146
62	PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation. <i>Frontiers in Immunology</i> , 2019 , 10, 630	8.4	57
61	PD-1 aborts the activation trajectory of autoreactive CD8 T cells to prohibit their acquisition of effector functions. <i>Journal of Autoimmunity</i> , 2019 , 105, 102296	15.5	10
60	PD-1 Research: History and Future Perspectives. <i>Trends in the Sciences</i> , 2019 , 24, 2_8-2_14	0	
59	Face of the Cover. <i>Trends in the Sciences</i> , 2019 , 24, 2_3-2_3	0	
58	Stimulatory and Inhibitory Co-signals in Autoimmunity. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1189, 213-232	3.6	7
57	PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR. <i>Biochemical and Biophysical Research Communications</i> , 2019 , 511, 491-497	3.4	5
56	Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation. <i>Journal of Biological Chemistry</i> , 2019 , 294, 6017-6026	5.4	23
55	Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells. <i>Journal of Biological Chemistry</i> , 2019 , 294, 19896-19906	5.4	16
54	Paradoxical development of polymyositis-like autoimmunity through augmented expression of autoimmune regulator (AIRE). <i>Journal of Autoimmunity</i> , 2018 , 86, 75-92	15.5	16
53	LAG-3 inhibits the activation of CD4 T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. <i>Nature Immunology</i> , 2018 , 19, 1415-1426	19.1	84

52	Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. <i>Cancer Science</i> , 2016 , 107, 189-202	6.9	3
51	A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. <i>Nature Immunology</i> , 2013 , 14, 1212-8	19.1	611
50	TNF- α s essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression. <i>Clinical Immunology</i> , 2013 , 146, 15-25	9	34
49	IFN- α s reciprocally involved in the concurrent development of organ-specific autoimmunity in the liver and stomach. <i>Autoimmunity</i> , 2012 , 45, 186-98	3	10
48	Intestinal CX3C chemokine receptor 1(high) (CX3CR1(high)) myeloid cells prevent T-cell-dependent colitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 5010-5 ^{11.5}	81	
47	BALB/c-Fcgr2bPdc1 mouse expressing anti-urothelial antibody is a novel model of autoimmune cystitis. <i>Scientific Reports</i> , 2012 , 2, 317	4.9	10
46	Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice. <i>Gastroenterology</i> , 2011 , 140, 1322-1333.e1-5	13.3	52
45	Role of PD-1 in regulating T-cell immunity. <i>Current Topics in Microbiology and Immunology</i> , 2011 , 350, 17-37	3.3	198
44	PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. <i>Journal of Experimental Medicine</i> , 2011 , 208, 395-407	16.6	191
43	IFN- γ directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. <i>Journal of Immunology</i> , 2011 , 186, 2772-9	5.3	227
42	PD-1-PD-L1 pathway impairs T(h)1 immune response in the late stage of infection with Mycobacterium bovis bacillus Calmette-Gu \acute{e} rin. <i>International Immunology</i> , 2010 , 22, 915-25	4.9	35
41	PD-1 deficiency results in the development of fatal myocarditis in MRL mice. <i>International Immunology</i> , 2010 , 22, 443-52	4.9	155
40	Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. <i>Journal of Immunology</i> , 2010 , 184, 2337-47	5.3	65
39	Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. <i>Cancer</i> , 2010 , 116, 1757-66	6.4	511
38	Identification of QTLs that modify peripheral neuropathy in NOD.H2b-Pdcd1 ^{-/-} mice. <i>International Immunology</i> , 2009 , 21, 499-509	4.9	8
37	T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions 2009 , 50, 2862-70		63
36	PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. <i>Journal of Immunology</i> , 2009 , 182, 6682-9	5.3	115
35	Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. <i>Gastroenterology</i> , 2008 , 135, 1333-43	13.3	87

34	PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3533-8	11.5	41
33	The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3011-6	11.5	264
32	The programmed death-1 and interleukin-10 pathways play a down-modulatory role in LP-BM5 retrovirus-induced murine immunodeficiency syndrome. <i>Journal of Virology</i> , 2008 , 82, 2456-69	6.6	13
31	The PD-1 and IL-10 pathways play a down-modulatory role in LP-BM5 retrovirus-induced murine immunodeficiency syndrome. <i>FASEB Journal</i> , 2008 , 22, 856.18	0.9	
30	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 3360-5	11.5	1081
29	Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function. <i>International Immunology</i> , 2007 , 19, 881-90	4.9	7
28	PD-1 and PD-1 ligands: from discovery to clinical application. <i>International Immunology</i> , 2007 , 19, 813-24	4.9	836
27	Rejuvenating exhausted T cells during chronic viral infection. <i>Cell</i> , 2006 , 124, 459-61	56.2	28
26	The PD-1-PD-L pathway in immunological tolerance. <i>Trends in Immunology</i> , 2006 , 27, 195-201	14.4	526
25	Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdc1-/- mice. <i>Journal of Experimental Medicine</i> , 2005 , 202, 1643-8	16.6	44
24	Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy. <i>Trends in Molecular Medicine</i> , 2005 , 11, 322-6	11.5	32
23	Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. <i>Nature Immunology</i> , 2005 , 6, 280-6	19.1	420
22	PD-1/PD-L pathway and autoimmunity. <i>Autoimmunity</i> , 2005 , 38, 353-7	3	70
21	Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 11823-8	11.5	306
20	Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome. <i>Journal of Rheumatology</i> , 2005 , 32, 2156-63	4.1	51
19	Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. <i>Nature Medicine</i> , 2003 , 9, 1477-83	50.5	495
18	PD-1 inhibits antiviral immunity at the effector phase in the liver. <i>Journal of Experimental Medicine</i> , 2003 , 198, 39-50	16.6	307
17	DCIR acts as an inhibitory receptor depending on its immunoreceptor tyrosine-based inhibitory motif. <i>Journal of Investigative Dermatology</i> , 2002 , 118, 261-6	4.3	70

16	New regulatory co-receptors: inducible co-stimulator and PD-1. <i>Current Opinion in Immunology</i> , 2002 , 14, 779-82	7.8	189
15	Microanatomical localization of PD-1 in human tonsils. <i>Immunology Letters</i> , 2002 , 83, 215-20	4.1	65
14	Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. <i>Immunology Letters</i> , 2002 , 84, 57-62	4.1	216
13	Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 12293-7	11.5	2044
12	PD-L2 is a second ligand for PD-1 and inhibits T cell activation. <i>Nature Immunology</i> , 2001 , 2, 261-8	19.1	2040
11	PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 13866-71	11.5	600
10	Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. <i>Science</i> , 2001 , 291, 319-22	33.3	1330
9	The regulation of PD-1/PD-L1 pathway and autoimmune diseases 2001 , 211-214		
8	Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. <i>Journal of Experimental Medicine</i> , 2000 , 192, 1027-34	16.6	3501
7	Natural killer activating receptors trigger interferon gamma secretion from T cells and natural killer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 3798-803	11.5	59
6	Pathophysiological significance of the obese gene product, leptin, in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats. <i>Endocrinology</i> , 1997 , 138, 947-54	4.8	116
5	RBP-L, a transcription factor related to RBP-Jkappa. <i>Molecular and Cellular Biology</i> , 1997 , 17, 2679-87	4.8	109
4	Genomic organization, expression, and chromosomal mapping of the mouse adrenomedullin gene. <i>Genomics</i> , 1996 , 37, 395-9	4.3	34
3	Molecular cloning of rat leptin receptor isoform complementary DNAs--identification of a missense mutation in Zucker fatty (fa/fa) rats. <i>Biochemical and Biophysical Research Communications</i> , 1996 , 225, 75-83	3.4	222
2	Structural organization and chromosomal assignment of the human obese gene. <i>Journal of Biological Chemistry</i> , 1995 , 270, 27728-33	5.4	111
1	Molecular cloning of rat obese cDNA and augmented gene expression in genetically obese Zucker fatty (fa/fa) rats. <i>Journal of Clinical Investigation</i> , 1995 , 96, 1647-52	15.9	160